MedPath

IMPLICIT BIOSCIENCE LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:4
Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (55.6%)
Phase 1
4 (44.4%)

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Phase 1
Recruiting
Conditions
STEMI
Stent Implantation
STEMI (ST Elevation MI)
STEMI - ST Elevation Myocardial Infarction (MI)
Interventions
Other: Placebo, 150 mL intravenously, once
First Posted Date
2024-11-07
Last Posted Date
2025-02-10
Lead Sponsor
Implicit Bioscience
Target Recruit Count
10
Registration Number
NCT06678074
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

IC14 for Treatment of Acute Decompensated Heart Failure

Phase 1
Recruiting
Conditions
Acute Decompensated Heart Failure
Interventions
First Posted Date
2024-08-16
Last Posted Date
2025-04-02
Lead Sponsor
Implicit Bioscience
Target Recruit Count
10
Registration Number
NCT06556810
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Anti-CD14 Treatment with IC14 in Hospitalized ARDS Patients

Phase 2
Not yet recruiting
Conditions
Adult Respiratory Distress Syndrome
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Acute Lung Injury
Acute Respiratory Distress Syndrome
Interventions
First Posted Date
2024-07-22
Last Posted Date
2024-11-07
Lead Sponsor
Implicit Bioscience
Target Recruit Count
56
Registration Number
NCT06513949
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Phase 1
Active, not recruiting
Conditions
Arrhythmogenic Right Ventricular Dysplasia
Arrhythmogenic Left Ventricular Cardiomyopathy
Arrhythmogenic Right Ventricular Cardiomyopathy 1
Arrhythmogenic Cardiomyopathy
ACM
ARVC
PKP2
Interventions
First Posted Date
2024-02-23
Last Posted Date
2025-05-11
Lead Sponsor
Implicit Bioscience
Target Recruit Count
5
Registration Number
NCT06275893
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

Conditions
COVID
ARDS, Human
Ards
SARS-CoV2
First Posted Date
2020-04-15
Last Posted Date
2021-06-21
Lead Sponsor
Implicit Bioscience
Registration Number
NCT04346277
Locations
🇮🇹

IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.